Zeo ScientifiX, Inc. Stock

Equities

ZEOX

US68621D2062

Pharmaceuticals

Market Closed - OTC Markets 10:59:53 2024-04-25 am EDT 5-day change 1st Jan Change
1.25 USD -11.35% Intraday chart for Zeo ScientifiX, Inc. -21.88% +22.55%
Sales 2022 6.49M Sales 2023 4.56M Capitalization 12.89M
Net income 2022 -8M Net income 2023 -6M EV / Sales 2022 5.78 x
Net cash position 2022 2.71M Net cash position 2023 1.06M EV / Sales 2023 2.59 x
P/E ratio 2022
-3.48 x
P/E ratio 2023
-1.78 x
Employees 23
Yield 2022 *
-
Yield 2023
-
Free-Float 59.49%
More Fundamentals * Assessed data
Dynamic Chart
Zeo ScientifiX, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024 CI
Zeo ScientifiX, Inc. has Changed its Ticker to ZEOX from OCEL CI
Organicell Regenerative Medicine, Inc. will Change its Name to Zeo ScientifiX, Inc CI
Organicell Regenerative Medicine, Inc. Reports Earnings Results for the Full Year Ended October 31, 2023 CI
Organicell Regenerative Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023 CI
Organicell Regenerative Medicine, Inc. announced a financing transaction CI
An unknown buyer acquired Laboratory Facility Located in Basalt, Colorado from Organicell Regenerative Medicine, Inc. for $1.25 million. CI
Organicell Regenerative Medicine, Inc. Reports Interim Results of Phase 1/2A Research Program CI
Organicell Regenerative Medicine, Inc. Announces Resignation of Maria Ines Mitrani as Director CI
Organicell Welcomes Howard Golub as Its New EVP/CSO CI
Organicell Regenerative Medicine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023 CI
Organicell Regenerative Medicine, Inc. Announces Executive Changes CI
Organicell Regenerative Medicine, Inc. Announces Management Changes CI
Organicell Regenerative Medicine, Inc. Terminates Albert Mitrani as Its Executive Vice President of Sales CI
Organicell Regenerative Medicine, Inc. Announces Termination of Dr. Maria Ines Mitrani as its Chief Scientific Officer CI
More news
1 day-11.35%
1 week-21.88%
Current month-37.42%
1 month-30.01%
3 months+4.17%
6 months-34.21%
Current year+22.55%
More quotes
1 week
1.25
Extreme 1.25
1.46
1 month
1.25
Extreme 1.25
2.20
Current year
1.02
Extreme 1.02
3.54
1 year
0.90
Extreme 0.896
4.80
3 years
0.90
Extreme 0.896
125.98
5 years
0.90
Extreme 0.896
125.98
10 years
0.70
Extreme 0.7
300.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 66 23-06-05
Director of Finance/CFO 63 16-11-03
Chief Tech/Sci/R&D Officer 71 23-06-05
Members of the board TitleAgeSince
Director of Finance/CFO 63 16-11-03
Director/Board Member 76 22-09-22
Director/Board Member 62 22-08-18
More insiders
Date Price Change Volume
24-04-25 1.25 -11.35% 811
24-04-24 1.41 +0.71% 128
24-04-23 1.4 -4.37% 1,662
24-04-22 1.464 +8.44% 7,652
24-04-19 1.35 -15.62% 8,124

Delayed Quote OTC Markets, April 25, 2024 at 10:59 am EDT

More quotes
Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company. It develops biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its products are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent and an autologous non-manipulated biologic containing the nanoparticle fraction from a patient’s own peripheral blood (RAAM Products). Its RAAM Products and related services are principally used in the health care industry, administered by doctors and clinics. The Company’s product, Zofin (Organicell Flow), is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs. Patient Pure X, its autologous product, is a non-manipulated biologic containing the nanoparticle fraction from a patient’s own peripheral blood.
More about the company

Annual profits - Rate of surprise